Literature DB >> 20108148

Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis: a case-matched study.

Benjamin Coquet-Reinier1, Stéphane V Berdah, Jean-Charles Grimaud, David Birnbaum, Pierre-Alain Cougard, Marc Barthet, Ariadne Desjeux, Vincent Moutardier, Christian Brunet.   

Abstract

BACKGROUND: Infliximab offers promising new therapeutic options for treatment of moderate to severe ulcerative colitis. However, several studies suggest that it increases postoperative complication rates for patients who later require a restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). This study aimed to assess the postoperative course of patients after laparoscopic IPAA, comparing those who had and those who had not received infliximab before surgery.
METHODS: The authors identified patients from their institution's IPAA database, finding 13 patients who had received preoperative infliximab treatment. Using age, gender, and type of procedure (2 or 3 stages) as criteria, they matched these cases with infliximab-naive patients drawn from the same database. The differences in perioperative data between the two groups were analyzed. Complications and their severity were assessed using the Strasberg classification.
RESULTS: No significant difference was found between patients treated with and those treated without infliximab for each variable studied, namely, mean operative time (353 vs. 355 min), complication rate (23 vs. 38%), and mean hospital stay (22 vs. 25 days).
CONCLUSION: The study findings showed no adverse impact from previous infliximab therapy on the laparoscopic IPAA postoperative course.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20108148     DOI: 10.1007/s00464-009-0861-0

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  25 in total

1.  Infliximab for patients with refractory ulcerative colitis.

Authors:  W Y Chey
Journal:  Inflamm Bowel Dis       Date:  2001-05       Impact factor: 5.325

2.  HIF-1 expression in healing wounds: HIF-1alpha induction in primary inflammatory cells by TNF-alpha.

Authors:  J E Albina; B Mastrofrancesco; J A Vessella; C A Louis; W L Henry; J S Reichner
Journal:  Am J Physiol Cell Physiol       Date:  2001-12       Impact factor: 4.249

3.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

4.  Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.

Authors:  Chinyu Su; Bruce A Salzberg; James D Lewis; Julius J Deren; Asher Kornbluth; David A Katzka; Robert B Stein; Douglas R Adler; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

5.  Infliximab for refractory ulcerative colitis.

Authors:  W Y Chey; A Hussain; C Ryan; G D Potter; A Shah
Journal:  Am J Gastroenterol       Date:  2001-08       Impact factor: 10.864

6.  Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.

Authors:  Chelliah R Selvasekar; Robert R Cima; David W Larson; Eric J Dozois; Jeffrey R Harrington; William S Harmsen; Edward V Loftus; William J Sandborn; Bruce G Wolff; John H Pemberton
Journal:  J Am Coll Surg       Date:  2007-05       Impact factor: 6.113

7.  Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?

Authors:  Wolfgang B Gaertner; Alejandra Decanini; Anders Mellgren; Ann C Lowry; Stanley M Goldberg; Robert D Madoff; Michael P Spencer
Journal:  Dis Colon Rectum       Date:  2007-09-27       Impact factor: 4.585

8.  Colectomy rate in acute severe ulcerative colitis in the infliximab era.

Authors:  A Aratari; C Papi; V Clemente; A Moretti; R Luchetti; M Koch; L Capurso; R Caprilli
Journal:  Dig Liver Dis       Date:  2008-05-09       Impact factor: 4.088

9.  Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?

Authors:  Stefanie J Schluender; Andrew Ippoliti; Marla Dubinsky; Eric A Vasiliauskas; Konstantinos A Papadakis; Ling Mei; Stephan R Targan; Phillip R Fleshner
Journal:  Dis Colon Rectum       Date:  2007-11       Impact factor: 4.585

10.  [Two stage videoassisted restorative proctocolectomy. Early experience of 12 cases].

Authors:  S V Berdah; M Barthet; O Emungania; P Orsoni; P Alliot; J C Grimaud; C Brunet
Journal:  Ann Chir       Date:  2004 Jul-Aug
View more
  18 in total

1.  Laparoscopic surgery for ulcerative colitis.

Authors:  Luca Stocchi
Journal:  Clin Colon Rectal Surg       Date:  2010-12

2.  Laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis and impact of anti-tumor necrosis factor on postoperative outcomes.

Authors:  Ernst Hanisch; Dimosthenis E Ziogas
Journal:  Surg Endosc       Date:  2011-06       Impact factor: 4.584

Review 3.  Surgical treatment of ulcerative colitis in the biologic therapy era.

Authors:  Alberto Biondi; Marco Zoccali; Stefano Costa; Albert Troci; Ettore Contessini-Avesani; Alessandro Fichera
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

Review 4.  [Refractory inflammatory bowel disease: surgical challenges].

Authors:  H J Buhr; A J Kroesen
Journal:  Chirurg       Date:  2013-11       Impact factor: 0.955

5.  The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery.

Authors:  Cheryl Lau; Marla Dubinsky; Gil Melmed; Eric Vasiliauskas; Dror Berel; Dermot McGovern; Andrew Ippoliti; David Shih; Stephan Targan; Phillip Fleshner
Journal:  Ann Surg       Date:  2015-03       Impact factor: 12.969

6.  Short-term outcomes of laparoscopic surgery for Crohn's disease patients treated with anti-tumor necrosis factor alpha agents.

Authors:  Tsuyoshi Hata; Tsunekazu Mizushima; Hideki Osawa; Hidekazu Takahashi; Naotsugu Haraguchi; Junichi Nishimura; Taishi Hata; Ichiro Takemasa; Masakazu Ikenaga; Kiyokazu Nakajima; Hirofumi Yamamoto; Kohei Murata; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2016-07-02       Impact factor: 2.549

Review 7.  Inflammatory bowel disease surgery in the biologic era.

Authors:  Linda Ferrari; Mukta K Krane; Alessandro Fichera
Journal:  World J Gastrointest Surg       Date:  2016-05-27

Review 8.  Recent results of laparoscopic surgery in inflammatory bowel disease.

Authors:  Hermann Kessler; Jonas Mudter; Werner Hohenberger
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

Review 9.  Association between preoperative tumor necrosis factor alpha inhibitor and surgical site infection after surgery for inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Motoi Uchino; Hiroki Ikeuchi; Junzo Shimizu; Hiroki Ohge; Seiji Haji; Toru Mizuguchi; Yasuhiko Mohri; Chizuru Yamashita; Yuichi Kitagawa; Katsunori Suzuki; Motomu Kobayashi; Masahiro Kobayashi; Fumie Sakamoto; Masahiro Yoshida; Toshihiko Mayumi; Koichi Hirata; Yoshio Takesue
Journal:  Surg Today       Date:  2020-04-10       Impact factor: 2.549

Review 10.  Strategies for the care of adults hospitalized for active ulcerative colitis.

Authors:  Suresh Pola; Derek Patel; Sonia Ramamoorthy; Elisabeth McLemore; Marianne Fahmy; Jesus Rivera-Nieves; John T Chang; Elisabeth Evans; Michael Docherty; Mark Talamini; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2012-07-24       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.